Clinical Trials
14 trialsNCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00968799 2023-08-08
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
Cantonal Hospital of St. Gallen
Phase NA Terminated
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT02608684 2022-03-23
PemCiGem
Cedars-Sinai Medical Center
Phase 2 Completed
NCT01275664 2018-05-22
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
GOG Foundation
Phase NA Terminated
NCT01936974 2018-02-20
PGA
Western Regional Medical Center
Phase 2 Terminated
NCT00470366 2017-11-28
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00511992 2017-07-02
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
University of Oklahoma
Phase 2 Completed
NCT01659554 2017-03-10
HIPEC
Columbia University
Phase 2 Terminated
NCT00588237 2016-01-20
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00702299 2016-01-01
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
University of Arizona
Phase 1 Completed
NCT00003896 2013-01-04
S9912 Combination Chemo in Stage III Ovarian Cancer,
SWOG Cancer Research Network
Phase 2 Completed
NCT00191334 2009-03-27
Gemcitabine in Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed